Nebenwirkungen · Comirnaty
Comirnaty XFG 30 micrograms/dose dispersion for injection Comirnaty XFG 30 micrograms/dose dispersion for injection in pre-filled syringe Comirnaty XFG 10 micrograms/dose dispersion for injection COVID−19 mRNA Vaccine · Abschnitt 4.8 · PDF-Seite 155
HOS-149171 · Präparat HOS-099980
Infants born to pregnant participants – after 2 doses of Comirnaty Study C4591015 (Study 9), a Phase 2/3, placebo-controlled study, evaluated a total of 346 pregnant participants who received Comirnaty (n = 173) or placebo (n = 173). Infants (Comirnaty n = 167 or placebo n = 168) were evaluated up to 6 months. No safety concerns were identified that were attributable to maternal vaccination with Comirnaty.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T16:00:00Z · SHA-256 6b1fcd6e0ff3b5c1ffd59f9dd3286f1609cca5902765a0cf59830512428fefdc · Passage 4e8bcc7a8b894b1bd4108796334db33bc374b6d8b958b6c9da0ef17240de33c7 · Zeichen 19853–20262 im Abschnitt